Dr Ranjini Satyadev, MD | |
14555 Levan Rd., #314, Livonia, MI 48154-1243 | |
(734) 464-4138 | |
(734) 293-5379 |
Full Name | Dr Ranjini Satyadev |
---|---|
Gender | Female |
Speciality | Physical Medicine And Rehabilitation |
Experience | 34 Years |
Location | 14555 Levan Rd., Livonia, Michigan |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1396776860 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | 4301062043 (Michigan) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
St Joe Mercy Hospital System Livonia | Livonia, MI | Hospital |
Entity Name | Specialists In Physical Medicine And Rehabilitation Plc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1144417411 PECOS PAC ID: 6709821978 Enrollment ID: O20050628000587 |
News Archive
The use of a commonly prescribed antibiotic is a major contributor to the spread of infection in hospitals by the 'superbug' MRSA, according to new research. The study also found that increasing measures to prevent infection - such as improved hygiene and hand washing - appeared to have only a small effect on reducing MRSA infection rates during the period studied.
Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.
ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that Genentech, a member of the Roche Group, today announced its receipt of a Refuse to File (RTF) letter from the US Food and Drug Administration (FDA) for the accelerated approval of the Biologic License Application (BLA) for trastuzumab-DM1, or T-DM1, submitted in July 2010.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Ranjini Satyadev, MD 9 Windward Pl, Grosse Pointe Farms, MI 48236-3780 Ph: (734) 464-4138 | Dr Ranjini Satyadev, MD 14555 Levan Rd., #314, Livonia, MI 48154-1243 Ph: (734) 464-4138 |
News Archive
The use of a commonly prescribed antibiotic is a major contributor to the spread of infection in hospitals by the 'superbug' MRSA, according to new research. The study also found that increasing measures to prevent infection - such as improved hygiene and hand washing - appeared to have only a small effect on reducing MRSA infection rates during the period studied.
Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.
ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that Genentech, a member of the Roche Group, today announced its receipt of a Refuse to File (RTF) letter from the US Food and Drug Administration (FDA) for the accelerated approval of the Biologic License Application (BLA) for trastuzumab-DM1, or T-DM1, submitted in July 2010.
› Verified 1 days ago
Jeff Scott Pierce, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 18312 Middlebelt Rd, Livonia, MI 48152 Phone: 248-680-9000 Fax: 248-680-2929 | |
Icelle Grace Villanueva Martinez, PT, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 36313 St Andrews Dr, Livonia, MI 48152 Phone: 248-805-2622 | |
Dr. Ayman Tarabishy, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 34020 7 Mile Rd Ste 101, Livonia, MI 48152 Phone: 248-516-5016 Fax: 248-516-5017 | |
Mrs. Urszula Michalski, RPTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 38777 West Six Mile Road, Suite 209 Supplemental Health Care, Livonia, MI 48152 Phone: 734-452-0395 Fax: 734-779-1361 | |
Dr. Steven Russell Hinderer, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 34020 7 Mile Rd Ste 102, Livonia, MI 48152 Phone: 734-622-9500 Fax: 734-622-9555 | |
Dr. Arti Patel Amin, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 14555 Levan Rd, Ste 314, Livonia, MI 48154 Phone: 734-542-1970 Fax: 734-293-5379 |